FDA Confirms Departure of Ronald Farkas (SRPT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Sarepta's (SRPT) Underperform Rating Reiterated at Jefferies
September 14, 2016 4:16 PM EDTJefferies reiterated an Underperform rating on Sarepta Therapeutic (NASDAQ: SRPT) with a price target of $7.00
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $25.60 yesterday.
... MoreSarepta (SRPT) PT Raised to $47 at Needham & Company; Sees Upside to $60
September 14, 2016 1:54 PM EDTNeedham & Company analyst Chad Messer raised his price target on Buy-rated Sarepta Therapeutic (NASDAQ: SRPT) to $47.00 (from $26.00), with upside to $60. Messer said "while we view the departure of FDA reviewer Dr. Ron Farkas as a potential positive for eteplirsen approval, we still believe the... More
FDA Confirms Ron Farkas No Longer at FDA (SRPT) - Bloomberg
September 14, 2016 10:18 AM EDTFDA Confirms Ron Farkas No Longer at FDA (Nasdaq: SRPT) - Bloomberg
... MoreFarkas' Departure a Positive for Sarepta (SRPT) Eteplirsen Approval - Oppenheimer
September 14, 2016 6:28 AM EDTOppenheimer's Sarepta Therapeutic (NASDAQ: SRPT) analyst Michelle Gilson said their checks suggest that Ronald Farkas, MD, PhD, has indeed left the FDA; additionally, he is no longer listed in the HHS employee directory.
They view this as a positive signal for eteplirsen... More
Sarepta Therapeutics (NASDAQ: SRPT) options priced for movement into expected FDA decision
September 14, 2016 6:11 AM EDTSarepta Therapeutics (NASDAQ: SRPT) is recently up $3.35 to $28.95 in the premarket on hope for a decision on the delayed FDA decision regarding eteplirsen. September call option implied volatility is at 131, September weekly is at 147, October is at 187; compared to its 52-week range of 68 to 399.
... MoreAfter-Hours Stock Movers 09/13: (SRPT) (HLF) Higher; (AGIO) (CALD) Lower (more...)
September 13, 2016 6:02 PM EDTToday's After-Hours Movers
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) 5% LOWER; announced that it is offering to sell, subject to market and other conditions, up to $150 million of its common stock in an underwritten public offering. Agios... More
Sarepta Therapeutics (SRPT) Surges After Hours
September 13, 2016 5:25 PM EDTSarepta Therapeutics (NASDAQ: SRPT) gaining on chatter Ron Farkas is no longer at the FDA. Shares are up 10%.
Seems like Ron Farkas is no longer at the @US_FDA cc $SRPT
jenn mcnary (@jennmcnary) September 13, 2016... More
